Spots Global Cancer Trial Database for First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Official Title: A First-in-human, Dose-escalation Followed by Expansion Study to Assess the Safety and Preliminary Efficacy of a Bispecific Antibody OT-A201 as Monotherapy and in Combination Therapy in Patients With Selected Hematological Malignancies and Solid Tumors
Study ID: NCT05828459
Study Description
Brief Summary: This phase 1 study is aimed at establishing the safety basis of OT-A201 in the treatment of hematological malignancies and solid tumors. In the dose of escalation part it is to characterize the overall safety and tolerability profile and determine the recommended dose(s) of OT-A201 as monotherapy, and in various combination regimens. Preliminary information about anti-cancer activity will be further explored in the expansion part of the study.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
ICM - Montpellier, Montpellier, , France
Saint-Eloi Hospital - Montpellier (CHU), Montpellier, , France
Saint-Joseph Hospital - Paris, Paris, , France
Centre Eugène Marquis, Rennes, , France
Contact Details
Name: Eric Raymond, MD, PhD
Affiliation: Saint-Joseph Hospital - Paris
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
